Jenrin on ‘Peripherally Selective’ Path to Treat Diabetes
Virtual biotech Jenrin Discovery LLC spent its first six years targeting peripherally selective (PS) CB1 receptor antagonists as a safer and more effective approach to treat diabetes and other metabolic disorders.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter